2004
DOI: 10.4161/cbt.3.12.1392
|View full text |Cite
|
Sign up to set email alerts
|

Cell cycle regulation and hepatocarcinogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
40
0

Year Published

2007
2007
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 56 publications
(42 citation statements)
references
References 84 publications
2
40
0
Order By: Relevance
“…Ectopic expression of Bax induces apoptosis with apoptosis-associated morphologic alterations, caspase activation, and subsequent substrate proteolysis (33,34). Increased cell turnover results in the selection of monoclonal hepatocyte populations that subsequently undergo genomic alterations that lead to the development of HCC (35). However, p53 showed no difference between the liver of wild-type and Cyp2e1-null mice treated with diethylnitrosamine (data not shown).…”
Section: Discussionmentioning
confidence: 75%
“…Ectopic expression of Bax induces apoptosis with apoptosis-associated morphologic alterations, caspase activation, and subsequent substrate proteolysis (33,34). Increased cell turnover results in the selection of monoclonal hepatocyte populations that subsequently undergo genomic alterations that lead to the development of HCC (35). However, p53 showed no difference between the liver of wild-type and Cyp2e1-null mice treated with diethylnitrosamine (data not shown).…”
Section: Discussionmentioning
confidence: 75%
“…One of the key factors contributing to hepatocellular carcinogenesis is the deregulation of cell cycle progression (Feng et al, 2011;Greenbaum, 2004). Cyclin-dependent kinase (Cdk) 10 is a Cdc2-related kinase, which was originally identified based on its homology to the Cdc2 PSTA1RE amino acid domain (Graña et al, 1994).…”
Section: Introductionmentioning
confidence: 99%
“…The overexpression of cyclins is generally associated with advanced-stage disease and poor prognosis in many types of cancers, including hepatocellular carcinoma (9)(10)(11)(12)(13). Although molecular agents targeting cyclin-dependent kinases (CDK) and other cell-cycle regulators have been extensively studied, their roles in cancer therapy were not established until recently, when the CDK inhibitor palbociclib was demonstrated to prolong the progression-free survival of breast cancer patients who received hormonal therapy (14)(15)(16).…”
Section: Introductionmentioning
confidence: 99%